14 completed, 5 terminated, 3 recruiting, 3 unknown. 29 Phase 3, 7 Phase 2.
Follow Huntington Disease: new trials by email Literature Review of Huntington Disease trials Research Report on Huntington Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pridopidine Phase 3 Study in Huntington's Disease Pridopidine, Placebo - Huntington Disease | Phase 3 | Recruiting | Prilenia | 400 | 2026-07-01 | 2026-11-04 |
| An Extension of SKY-0515 in Participants With Huntington's Disease SKY-0515 - Huntington's Disease (HD) | Phase 2 / Phase 3 | Enrolling by invitation | Skyhawk Therapeutics, Inc. | 500 | 2026-04-10 | 2026-07-24 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease Votoplam (blinded), Placebo - Huntington Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 770 | 2026-03-24 | 2026-09-22 |
| Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease | Phase 2 / Phase 3 | Recruiting | Skyhawk Therapeutics, Inc. | 400 | 2026-01-06 | 2026-10-29 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| Efficacy and Safety of NestaCell® in Huntington's Disease NestaCell® - Huntington Disease | Phase 3 | Unknown | Azidus Brasil | 120 | 2024-06-08 | 2023-10-24 |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Valbenazine - Chorea, Huntington | Phase 3 | Enrolling by invitation | Neurocrine Biosciences | 7 | 2024-04-24 | 2026-06-18 |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease SAGE-718 - Huntington's Disease | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 153 | 2022-12-14 | 2025-12-17 |
| TEsting METformin Against Cognitive Decline in HD Metformin, Placebo - Huntington Disease | Phase 3 | Completed | Instituto de Investigacion Sanitaria La Fe | 60 | 2022-04-11 | 2025-09-25 |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease Deutetrabenazine - Huntington Disease | Phase 2 / Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 30 | 2021-11-19 | 2026-08-05 |
| PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD Pridopidine, Placebo - Huntington Disease | Phase 3 | Completed | Prilenia | 499 | 2020-10-16 | 2025-03-12 |
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Valbenazine - Chorea, Huntington | Phase 3 | Terminated | Neurocrine Biosciences | 154 | 2020-09-18 | 2026-11-03 |
| Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. Cellavita-HD - Huntington Disease | Phase 2 / Phase 3 | Unknown | Azidus Brasil | 35 | 2020-02-10 | 2022-10-28 |
| Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Valbenazine, Placebo - Chorea, Huntington | Phase 3 | Completed | Neurocrine Biosciences | 128 | 2019-11-13 | 2023-10-11 |
| Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo - Huntington Disease, Irritability | Phase 3 | Completed | The University of Texas Health Science Center, Houston | 20 | 2019-08-05 | 2024-01-05 |
| An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies RO7234292 (RG6042) - Huntington Disease | Phase 3 | Completed | Hoffmann-La Roche | 236 | 2019-04-23 | 2023-08-31 |
| Alternatives for Reducing Chorea in Huntington Disease SD-809 - Chorea Associated With Huntington Disease | Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 119 | 2013-11-12 | 2021-11-09 |
| First Time Use of SD-809 in Huntington Disease SD-809, Placebo - Chorea | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 90 | 2013-08-05 | 2017-09-20 |
| Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) RP103, Placebo - Huntington's Disease | Phase 2 / Phase 3 | Unknown | University Hospital, Angers | 96 | 2010-10-01 | 2014-04-02 |
| An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease Dimebon (latrepirdine) - Huntington Disease | Phase 3 | Terminated | Medivation, Inc. | 362 | 2010-02-01 | 2016-10-12 |
Showing 20 of 29. Sign in to see all of them.
Chorea (4) · Lymphoma, Follicular (1) · Mitochondrial Diseases (1) · Movement Disorders (1)
Basal Ganglia Diseases (29) · Brain Diseases (29) · Central Nervous System Diseases (29) · Cognition Disorders (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29) · Dementia (29) · Dyskinesias (29) · Genetic Diseases, Inborn (29) · Heredodegenerative Disorders, Nervous System (29) · Mental Disorders (29) · Nervous System Diseases (29) · Neurocognitive Disorders (29) · Neurodegenerative Diseases (29) · Movement Disorders (28) · Chorea (25)
deutetrabenazine (3) · pridopidine (3) · valbenazine (3) · Tetrabenazine (2) · latrepirdine (2) · Biguanides (1) · Cell- and Tissue-Based Therapy (1) · Creatine (1) · Dextromethorphan (1) · Docosahexaenoic Acids (1) · Glucose (1) · Hypoglycemic Agents (1) · Metformin (1) · Minocycline (1) · Olanzapine (1)
Neurocrine Biosciences (3) · Skyhawk Therapeutics, Inc. (3) · Azidus Brasil (2) · Massachusetts General Hospital (2) · Medivation, Inc. (2) · Prilenia (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Amarin Neuroscience Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · Auspex Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1) · Instituto de Investigacion Sanitaria La Fe (1) · Merit Cudkowicz (1) · Novartis Pharmaceuticals (1) · Prestwick Pharmaceuticals (1)
United States (17) · Canada (16) · Australia (9) · United Kingdom (8) · Germany (7) · Spain (7) · France (6) · Italy (5) · Netherlands (4) · Austria (3) · Belgium (3) · Czechia (3) · New Zealand (3) · Poland (3) · Portugal (3)
Amy E Brown, MD (1) · Blair Leavitt, MD (1) · Christopher Ross, MD, PhD (1) · Diana Rosas, MD, MS (1) · Erin L Furr Stimming, MD (1) · Fred Marshall, M.D. (1) · Giovanni Schifitto, MD (1) · Ira Shoulson, MD (1)
PMID 28265459, PMID 35747889, PMID 38557959, PMID 39825184, PMID 19064745, PMID 20021666, PMID 22071279, PMID 23108692, PMID 26714284, PMID 27380342, PMID 27913695, PMID 28701493, PMID 29480210, PMID 30103342, PMID 30850442, PMID 32250312, PMID 36242718, PMID 36811812, PMID 37210099, PMID 40913168, PMID 41499296
2018 (1), R01NS052619 (1), U01AT000613 (1), U01NS052592 (1)